- Home
- INDV vs VKTX Comparison
INDV vs VKTX Comparison
Compare INDV & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INDV | VKTX |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | INDV | VKTX |
|---|---|---|
| Price | $35.82 | $34.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $32.50 | ★ $87.07 |
| AVG Volume (30 Days) | ★ 3.4M | 2.5M |
| Earning Date | 10-30-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $1,180,000,000.00 | N/A |
| Revenue This Year | $1.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.62 | $18.92 |
| 52 Week High | $38.00 | $45.00 |
Technical Indicators
Market Signals| Indicator | INDV | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 45.58 |
| Support Level | $34.91 | $36.49 |
| Resistance Level | $36.18 | $36.38 |
| Average True Range (ATR) | 0.92 | 1.92 |
| MACD | -0.20 | -0.37 |
| Stochastic Oscillator | 48.00 | 19.18 |
Price Performance
Historical ComparisonAbout INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.